- NCIt
- C7158
Loading cancer entity…
Loading cancer entity…
Clinical trials
15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00050752 | Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer | recruiting | — | 1,130 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | not yet recruiting | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06159166 |
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) |
| recruiting |
| Phase 1 / Phase 2 |
| 24 |
| Johns Hopkins UniversityOTHER |
| 1 |
| Apr 13, 2026 |
| clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT00975819 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | completed | Phase 2 | 61 | Denise Martin AdamsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05581511 | Natural History Study of Cutaneous Neurofibromas in People With NF1(cNF Natural Hx) | active not recruiting | — | 500 | Johns Hopkins UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02110069 | A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | terminated | Phase 2 | 4 | Boston Children's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT00540566 | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | completed | — | 113 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |